LY2951742

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

Migraine DisordersMigraine HeadacheMigrainesOsteoarthritis, Knee

Phase 1

A Study of LY2951742 in Healthy Volunteers

CompletedNCT01337596

Eli Lilly and CompanyMigraines

Start: 2011-04-30End: 2012-04-30Updated: 2019-02-20

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

CompletedNCT02104765

Eli Lilly and CompanyMigraine Disorders

Start: 2014-06-30End: 2015-01-31Updated: 2019-06-14

Phase 2

A Study of LY2951742 in Participants With Migraine

CompletedNCT01625988

Eli Lilly and CompanyMigraine Headache

Start: 2012-06-28End: 2013-09-18Updated: 2020-01-09

A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

TerminatedNCT02192190

Eli Lilly and CompanyOsteoarthritis, Knee

Start: 2014-07-31End: 2015-06-30Updated: 2019-09-10

Related Papers

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

The Journal of Headache and Pain2020-06-2317 citations

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

Journal of Neurology Neurosurgery & Psychiatry2019-04-1940 citations

CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.

2018-09-1845 citations

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

2014-08-10267 citations